Related Experiment Videos
Is combination therapy for chronic hepatitis C toxic for cardiac function?
Ramzy Almawardy1, Walid Elhammady, Nasser Mousa
1Cardiology Department, Ain Shams University, Egypt.
Hepatitis Monthly
|October 30, 2012
Summary
Combination therapy with pegylated interferon and ribavirin for chronic hepatitis C did not significantly impact cardiac function. This treatment may be safely used in patients without pre-existing cardiac conditions.
Area of Science:
- Cardiology
- Hepatology
- Pharmacology
Background:
- Interferon therapy is associated with various cardiovascular complications.
- Potential cardiac adverse effects include arrhythmias, impaired cardiac function, myocardial ischemia, and reduced left ventricular function.
Purpose of the Study:
- To assess the impact of combination therapy (pegylated interferon and ribavirin) on left ventricular systolic and diastolic functions.
- To evaluate cardiac safety in patients with chronic hepatitis C infection undergoing this treatment.
Main Methods:
- 120 patients with chronic hepatitis C eligible for combination therapy were enrolled.
- Comprehensive cardiovascular assessments, including ECG and echocardiography, were performed at baseline and after six months of treatment.
- Evaluation included medical history, clinical examination, and cardiac function parameters.
Main Results:
- No significant changes in cardiac symptoms (shortness of breath, palpitations, chest pain, hypertension) were observed.
- Electrocardiogram (ECG) showed non-significant changes in QT and corrected QT intervals.
- Echocardiography revealed no statistically significant differences in cardiac parameters post-treatment compared to baseline.
Conclusions:
- Combination therapy of pegylated interferon and ribavirin does not significantly impair cardiac function in chronic hepatitis C patients.
- This treatment regimen appears safe for patients without pre-existing cardiac disease.
Related Concept Videos
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:25Hepatitis
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...